Janux Therapeutics (JANX) Income towards Parent Company (2020 - 2025)
Historic Income towards Parent Company for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$24.3 million.
- Janux Therapeutics' Income towards Parent Company rose 1335.04% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.9 million, marking a year-over-year decrease of 6832.13%. This contributed to the annual value of -$69.0 million for FY2024, which is 1835.73% down from last year.
- As of Q3 2025, Janux Therapeutics' Income towards Parent Company stood at -$24.3 million, which was up 1335.04% from -$33.9 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Income towards Parent Company ranged from a high of -$2.3 million in Q1 2021 and a low of -$33.9 million during Q2 2025
- Its 5-year average for Income towards Parent Company is -$16.0 million, with a median of -$16.1 million in 2022.
- In the last 5 years, Janux Therapeutics' Income towards Parent Company plummeted by 75716.56% in 2021 and then surged by 6596.41% in 2024.
- Janux Therapeutics' Income towards Parent Company (Quarter) stood at -$13.4 million in 2021, then fell by 19.75% to -$16.1 million in 2022, then grew by 26.81% to -$11.8 million in 2023, then tumbled by 71.93% to -$20.2 million in 2024, then dropped by 20.27% to -$24.3 million in 2025.
- Its last three reported values are -$24.3 million in Q3 2025, -$33.9 million for Q2 2025, and -$23.5 million during Q1 2025.